Coexistence of Somatostatin-immunoreactivity in an Adrenal Pheochromocytoma and a Thyroid Medullary Carcinoma (Sipple syndrome)

N. Bethge; S. Ahuja; F. Diel; K. H. Usadel

doi:10.1055/s-0029-1210748

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 1988; 91(2): 217-222
DOI: 10.1055/s-0029-1210748

Original

Coexistence of Somatostatin-immunoreactivity in an Adrenal Pheochromocytoma and a Thyroid Medullary Carcinoma (Sipple syndrome)

N. Bethge, S. Ahuja, F. Diel, K. H. Usadel^*

Institut für Pathologie, Strahlenklinik und Poliklinik, Universitätsklinikum Steglitz, Freie Universität Berlin, Universität Heidelberg
^* Zentrum der Inneren Medizin der Johann-Wolfgang-Goethe-Universität, Abteilung für Endokrinologie, Frankfurt am Main, II. Medizinische Klinik, Klinikum Mannheim, Universität BRD

Abstract

PDF Download

Summary

The presence of somatostatin-immunoreactivity in tumor tissue of adrenal pheochromocytoma and thyroid medullary carcinoma identified by peroxidase-antiperoxidase technique is reported in one case of Sipple syndrome. This patient was found to have a high concentration of somatostatin-immunoreactivity in the peripheral blood (40 ng/l, normal 0-20 ng/l). After removal of the tumors, the plasma somatostatin-immunoreactivity fell within normal range (12.5 ng/l).

This seems to be the first report of Sipple syndrome that produces somatostatin-immunoreactivity in both: pheochromocytoma and thyroid medullary carcinoma.

Key words

Sipple syndrome - Somatostatin - Pheochromocytoma - Thyroid medullary carcinoma

PDF (270 kb)